Y Intercept Hong Kong Ltd Reduces Stock Position in HCA Healthcare, Inc. (NYSE:HCA)

Y Intercept Hong Kong Ltd lessened its position in HCA Healthcare, Inc. (NYSE:HCA) by 44.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,016 shares of the company’s stock after selling 4,727 shares during the period. Y Intercept Hong Kong Ltd’s holdings in HCA Healthcare were worth $2,445,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Alpha DNA Investment Management LLC acquired a new position in HCA Healthcare in the third quarter valued at $869,000. EP Wealth Advisors LLC lifted its holdings in shares of HCA Healthcare by 1.6% during the 2nd quarter. EP Wealth Advisors LLC now owns 225,146 shares of the company’s stock worth $72,335,000 after acquiring an additional 3,516 shares during the period. AustralianSuper Pty Ltd grew its holdings in HCA Healthcare by 118.5% in the third quarter. AustralianSuper Pty Ltd now owns 35,493 shares of the company’s stock valued at $14,425,000 after purchasing an additional 19,247 shares during the period. Quantinno Capital Management LP boosted its holdings in shares of HCA Healthcare by 55.9% in the 3rd quarter. Quantinno Capital Management LP now owns 31,750 shares of the company’s stock valued at $12,904,000 after purchasing an additional 11,380 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its holdings in shares of HCA Healthcare by 3.3% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 162,654 shares of the company’s stock worth $52,257,000 after buying an additional 5,136 shares during the last quarter. 62.73% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at HCA Healthcare

In related news, insider Erol R. Akdamar sold 2,900 shares of the business’s stock in a transaction dated Thursday, November 14th. The shares were sold at an average price of $353.00, for a total transaction of $1,023,700.00. Following the completion of the sale, the insider now owns 6,843 shares of the company’s stock, valued at $2,415,579. This represents a 29.76 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Michael S. Cuffe sold 8,358 shares of the stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $385.42, for a total value of $3,221,340.36. Following the sale, the executive vice president now owns 29,678 shares in the company, valued at $11,438,494.76. The trade was a 21.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 15,155 shares of company stock worth $5,608,990 over the last 90 days. Insiders own 1.70% of the company’s stock.

HCA Healthcare Stock Performance

Shares of HCA stock opened at $318.46 on Tuesday. The company’s 50-day simple moving average is $362.09 and its 200-day simple moving average is $358.91. HCA Healthcare, Inc. has a one year low of $255.73 and a one year high of $417.14. The stock has a market capitalization of $80.67 billion, a price-to-earnings ratio of 14.30, a PEG ratio of 1.23 and a beta of 1.63. The company has a debt-to-equity ratio of 48.71, a quick ratio of 1.00 and a current ratio of 1.12.

HCA Healthcare Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, December 27th. Investors of record on Friday, December 13th will be given a dividend of $0.66 per share. This represents a $2.64 annualized dividend and a dividend yield of 0.83%. The ex-dividend date is Friday, December 13th. HCA Healthcare’s dividend payout ratio is currently 11.85%.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on HCA shares. Oppenheimer upped their price target on HCA Healthcare from $390.00 to $400.00 and gave the stock an “outperform” rating in a research note on Monday, October 28th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $392.00 price target on shares of HCA Healthcare in a research report on Tuesday, October 1st. Wells Fargo & Company downgraded shares of HCA Healthcare from an “equal weight” rating to an “underweight” rating and cut their target price for the company from $400.00 to $320.00 in a research note on Monday, November 25th. TD Cowen lowered their price target on HCA Healthcare from $450.00 to $440.00 and set a “buy” rating for the company in a report on Monday, October 28th. Finally, StockNews.com lowered HCA Healthcare from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $380.29.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.